Drug Profile
Research programme: skin disorders therapy - Starpharma/Stiefel Laboratories
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Starpharma; Stiefel Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Skin-disorders in Unknown (Topical)
- 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline